BMYMP
BRISTOL MYERS SQUIBB CO
Key Financials
Revenue
$48.2B
↓ 0.2%
Net Income
$7.1B
↑ 178.8%
Operating Income
$1.4B
N/A
Gross Profit
$30.7B
↑ 276.9%
Total Liabilities
$71.5B
↓ 6.1%
Total Assets
$90.0B
↓ 2.8%
Shareholders' Equity
$18.5B
↑ 13.1%
EPS (Diluted)
$3.46
↑ 178.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 10-Q | 7/30/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BMYMP |
| Company Name | BRISTOL MYERS SQUIBB CO |
| CIK | 14272 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6092524621 |